急性髓系白血病基于抗体免疫疗法的研究进展  

Research Progress in Antibodies Based Immunotherapy for Acute Myeloid Leukemia

作　　者：刘天娇 李英花[1] LIU Tianjiao;LI Yinghua(Department of Hematology,the First Affiliated Hospital,Harbin Medical University,Harbin 150001,China)

机构地区：[1]哈尔滨医科大学附属第一医院血液内科,哈尔滨150001

出　　处：《医学综述》2021年第4期722-726,共5页Medical Recapitulate

基　　金：哈尔滨医科大学研究生实践创新项目(YJSSJCX2108-15HYD)。

摘　　要：目前急性髓系白血病(AML)的诱导化疗方案仍以蒽环类药物和阿糖胞苷为基础,然后进行不同方案的巩固化疗。对于复发或难治的患者推荐进行同种异体造血干细胞移植治疗,但预后仍不容乐观,联合化疗患者的5年生存率不足20%。AML患者造血干细胞移植成功与否主要取决于供体免疫细胞攻击和杀死宿主白血病细胞的能力,表明AML具有免疫反应性,因此免疫治疗前景可观,其中基于抗体的免疫疗法有望改善疗效并降低化疗药物的毒性。In recent decades,the induction chemotherapy regimen for acute myeloid leukemia(AML)is still based on anthracyclines and cytarabine,followed by different regimens of consolidation chemotherapy.Allogeneic hematopoietic stem cell transplantation is recommended for relapsed or refractory patients,but the prognosis is still not optimistic.The 5-year survival rate of the patients treated with combined chemotherapy is less than 20%.The success of hematopoietic stem cell transplantation in patients with AML mainly depends on the ability of donor immune cells to attack and kill host leukemia cells,indicating that AML is immunoreactive,and the prospects for immunotherapy are promising,among which antibody-based immunotherapy is expected to improve the efficacy and reduce the toxicity of chemotherapeutic drugs.

关 键 词：急性髓系白血病 抗体疗法 抗体药物偶联 抗体依赖性细胞毒性疗法 免疫检查点抑制剂 

分 类 号：R551[医药卫生—血液循环系统疾病]